MIR155: MIR155 is a noncoding transcript of the B-cell integration cluster gene that has been implicated in various biological processes and diseases, including osteogenesis, adipose tissue inflammation, autophagy, and cancer [PMC9288680] [PMC9839347] [PMC5617927] [PMC4389881] [PMC8761951]. It has been shown to play a role in osteogenic differentiation and bone regeneration, with its inhibition leading to increased osteogenesis of mesenchymal stem cells (MSCs) [PMC9288680]. MIR155 has also been found to be involved in adipose tissue inflammation and metabolic profile in an obesity setting, with its loss resulting in reduced M1 macrophage accumulation and improved metabolic profile [PMC5617927]. Additionally, MIR155 has been shown to regulate autophagic activity and is implicated in hypoxia-induced autophagy [PMC4389881]. It has also been reported that MIR155 expression does not affect the expression of anti-CD19 CAR (chimeric antigen receptor) in CAR retroviral vectors [PMC8761951]. Furthermore, MIR155 expression is reduced by certain anti-parasitic drugs in Th17 cells [PMC8169650]. The cell type-specific role of MIR155 in vascular calcification remains to be investigated using specific knockout or overexpression mouse models [PMC7810936]. In cancer research, MIR155 has been described as a key player involved in the pathogenesis of various hematologic malignancies and as part of exosomal cargo. It is also associated with breast cancer progression and diagnosis when examined along with other miRNAs such as miR10b, miR34a, and miR141. However, its association with ET resistance remains unknown. Additionally, MIR155 is known for its pro-inflammatory effects under hyperlipidemic conditions but not under normal conditions [PMC7912829] [PMC6607238] [PMC3338496].